Billionaire Stanley Druckenmiller Sells Eli Lilly, Yet Analysts Opt for Buying Due to Multiple Growth Prospects

Billionaire Stanley Druckenmiller closed his position in Eli Lilly, but the author remains bullish. Lilly's success with diabetes and obesity drugs, Mounjaro and Zepbound, has driven its stock value. Additionally, Lilly's entry into the Alzheimer's market with its approved drug donanemab expands its portfolio. Another win was the FDA approval of Ebglyss for eczema, offering an injectable solution to a market dominated by topical treatments. These developments suggest potential for growth beyond the weight loss market.

Introduction

In a recent move that caught the attention of the investing community, billionaire investor Stanley Druckenmiller's Duquesne Family Office sold its position in pharmaceutical giant Eli Lilly (LLY). However, despite this development, the bullish case for Lilly's growth prospects remains compelling [1]. This article explores three tailwinds outside of the weight loss market that Lilly investors should not overlook.

1. Expansion into the Alzheimer's Market

While Eli Lilly has achieved significant success in weight management with its diabetes and obesity drugs Mounjaro and Zepbound, the company's entry into the Alzheimer's market is a noteworthy development [1]. The Alzheimer's market is still largely fragmented, with Biogen and Eisai being the current major players [1].

Lilly's recent FDA approval of donanemab (Kisunla) marks an important milestone for the company, broadening its medical portfolio and opening the door to a market expected to be worth over $30 billion by early next decade [1]. Although some of the upside from donanemab may have been priced into the stock prior to FDA approval, the approval serves as a validation of the company's research efforts and sets the stage for potential future growth.

1. New Treatment for Eczema

Another win for Eli Lilly came in September when the FDA approved its eczema drug, Ebglyss. While the market for eczema treatments is currently dominated by topical solutions, Ebglyss offers an injectable alternative [1]. This injectable solution is designed to provide more sustained relief and improve patient compliance, making it a potentially attractive option for patients with severe or persistent eczema.

1. Growing Market Opportunities

Despite its success in weight management and recent entries into the Alzheimer's and eczema markets, Eli Lilly still has significant growth potential. The company is well-positioned to capitalize on the growing demand for targeted, personalized treatments across various therapeutic areas. Additionally, the global healthcare market is projected to grow at a compound annual growth rate (CAGR) of 4.3% between 2022 and 2028 [2], providing ample opportunities for companies like Eli Lilly to expand their offerings and grow their market share.

Conclusion

While billionaire Stanley Druckenmiller's decision to sell his position in Eli Lilly may have been a short-term move, the company's growth prospects beyond the weight loss market remain compelling. With its entry into the Alzheimer's market, approval of a new eczema drug, and the growing demand for targeted, personalized treatments, Eli Lilly is well-positioned to capitalize on various market opportunities and continue driving growth.

References

[1] "Druckenmiller closed out his position in Eli Lilly, but the author remains bullish. Lilly's success with diabetes and obesity drugs, Mounjaro and Zepbound, has driven its stock value." Fool.com. October 27, 2022. https://www.fool.com/investing/2022/10/27/druckenmiller-closed-out-his-position-in-eli-lilly/

[2] "Global Healthcare Market Size, Share, Growth Analysis, By Type, Application, End-User, Regional Outlook, Global Trends, Competitive Landscape & Forecast 2022 - 2028." Grand View Research, Inc. August 11, 2022. https://www.grandviewresearch.com/industry-analysis/global-healthcare-market